Navigation Links
Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
Date:8/6/2008

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Aug. 6 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, sell and distribute CIP-ISOTRETINOIN in the United States, its territories and possessions.

CIP-ISOTRETINOIN is a novel, patented formulation of isotretinoin, which is used in the treatment of severe nodular acne. The product received approvable letters from the U.S. Food and Drug Administration ("FDA") in May 2006 and April 2007 in which the FDA requested that Cipher provide additional clinical safety data. Cipher and its advisors are currently in discussions with the FDA's Division of Dermatology and Dental Products regarding the appropriate design of a safety study.

Under the terms of the agreement with RPI, Cipher received an initial upfront milestone payment of US$1 million. The agreement includes additional pre- and post-commercialization milestone payments of up to US$23 million, contingent upon the achievement of certain milestone targets. Once the product is successfully commercialized, Cipher will also receive a royalty in the mid-teens on net sales. In addition, RPI will reimburse Cipher for all costs associated with the clinical studies required to obtain FDA approval, up to a predetermined cap. Any additional development costs associated with initial FDA approval will be shared equally. Cipher is responsible for all product development activities, including management of the clinical studies required by the FDA to secure NDA approval. Cipher is also responsible for product supply and manufacturing, which would be fulfilled by its partner, Galephar Pharmaceutical Research. After product-related expenses are deducte
'/>"/>

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ciphers revised NDA for CIP-TRAMADOL ER accepted for review by FDA
2. Cipher provides regulatory update for CIP-TRAMADOL ER
3. Cipher provides CIP-TRAMADOL ER regulatory update
4. Cipher appoints Stefan Aigner to board of directors
5. Cipher Appeals FDAs Decision On CIP-TRAMADOL ER
6. Cipher reports third quarter fiscal 2007 results
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... (PRWEB) September 21, 2014 "I wanted ... without having to consume sugary, foul-tasting energy drinks," said ... not always just want to drink plain, old coffee. ... energy booster." , He developed ENERG CHEWING GUM to ... with weight loss. The formula contains nutritious vitamins, minerals ...
(Date:9/21/2014)... The Illinois Joining Forces Behavioral ... statewide symposium ( tinyurl.com/ILBHC14 ) focused on improving ... Sponsored by the VNA Foundation, Thresholds, Illinois Department ... Health & Disability Advocates, the symposium will be ... in Springfield, IL. The symposium features keynote ...
(Date:9/21/2014)... 21, 2014 The Electronic Medical ... supports electronic medical records (EMR) and electronic health ... healthcare legislation during the past five years and ... the five years to 2019. The 2009 Health ... established Medicare and Medicaid incentives to encourage the ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes in fashion garments ... implement a new shopping cart software on its website. ... Furthermore, the company has unveiled a new collection of ... items come in fashionable designs; all of them are ... off. "We are happy to release the new beach ...
(Date:9/21/2014)... accommodate the ever-growing customer base, Angeldress.co.uk decided to implement ... the company has unveiled its 2014 vintage wedding ... gowns, Angeldress.co.uk wants to make sure that all customers ... Its high quality vintage wedding outfits are now available ... off. , Online shopping is becoming more and more ...
Breaking Medicine News(10 mins):Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... , ... procedure to reshape the inner vaginal lips, may be considered medically necessary when large or ... cases like these, Chicago-area plastic surgeon Allan Parungao, MD, works with patients to help get ... ...
... Readers can ... Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian Catering. , ... (PRWEB) May 6, 2010 -- Individuals looking for ... of “A must have...The Maroema Cook Book” by Mamta Reid. With a lightweight, compact design ...
... with dementia are six times more likely to develop the ... to results of a 12-year study led by Johns Hopkins, ... the researchers saw among caregivers was on par with the ... Alzheimer,s disease, they report in the May Journal of ...
... 6, 2010 Results from the SPIRIT IV clinical ... Therapeutics (TCT) 2009 scientific symposium, were published today in ... Data from the trial, a large-scale multi-center study of ... stents demonstrated enhanced safety and efficacy in the treatment ...
... outbreak began, finds this flu had new targets , WEDNESDAY, ... flu first appeared, the World Health Organization has issued perhaps ... , "Here,s the definitive reference that shows in black-and-white what ... Dr. John Treanor, a professor of medicine and of microbiology ...
... ... the Global Embolization Symposium and Technologies (GEST) Meeting. Focus is on Benefit of Embolization ... ... a U.S.-based subsidiary of Terumo Corporation, today announced its educational program for the 4th ...
Cached Medicine News:Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 2Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 3Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 4Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:Spouses who care for partners with dementia at sixfold higher risk of same fate 2Health News:Spouses who care for partners with dementia at sixfold higher risk of same fate 3Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:H1N1 Often Hit the Young and Healthy 2Health News:H1N1 Often Hit the Young and Healthy 3Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 2Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 3Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 4
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... , SAN DIEGO, Sept. 8 ... ("Stemedica"), a world leader in stem cell research and manufacturing, ... and Trademark Office ("USPTO") for a proprietary methodology in the ... the USPTO on August 27th of this year. The ...
... MELBOURNE, Australia, Sept. 3 Cytopia Limited,s (ASX: CYT) ... Food and Drug Administration (FDA) review. CYT387 is a small-molecule ... The company,s IND application is now active and Cytopia is ... United States. , , CYT387 will be ...
Cached Medicine Technology:United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 2United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 3Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials 2
... Plate Shaker are designed to give reliable performance ... microplates. The on/off button, power supply socket and ... of the unit. The speed knob is located ... of speed from a minimum 950 rpm to ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
The BD LSR II can be configured with up to four fixed alignment lasers and the ability to detect up to 15 colors, utilizing a revolutionary optical design. The BD LSR II can be configured with a 488 ...
Modular flow cytometer with all options....
Medicine Products: